Vera Therapeutics (VERA) Accumulated Expenses (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Accumulated Expenses data on file, last reported at $31.2 million in Q1 2026.

• Quarterly Accumulated Expenses rose 173.05% year-over-year to $31.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.2 million (up 173.05% YoY) and the FY2025 annual result came in at $31.6 million, up 362.58% from the prior year.
• Accumulated Expenses slipped to $31.2 million in Q1 2026, from $31.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $31.6 million in Q4 2025 to a low of $1.1 million in Q1 2023.
• A 5-year average of $12.5 million and a median of $9.8 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses tumbled 64.14% — and 2025, when it jumped 656.86%.
• Tracing VERA's Accumulated Expenses over 5 years: stood at $11.0 million in 2022, then plunged by 64.14% to $3.9 million in 2023, then soared by 73.5% to $6.8 million in 2024, then surged by 362.58% to $31.6 million in 2025, then retreated by 1.0% to $31.2 million in 2026.
• The last three Accumulated Expenses figures came in at $31.2 million (Q1 2026), $31.6 million (Q4 2025), and $23.5 million (Q3 2025), per Business Quant data.